This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) June 3, 2023
✳️10 tweet #NephJC catch-up ✳️
🌟Let’s recap the RITAZAREM trial - a rematch between Rituximab and Azathioprine as the maintenance agent of choice in relapsed ANCA-associated vasculitis.
🌟Have we witnessed the ultimate triumph of Rituximab? pic.twitter.com/HbFKhe6MKc
